Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with…

By K. Dickstein, J. Kjekshus. The Lancet, 2002

1,193 citations recorded by the source corpus.

Citations in the corpus

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. (2008, background): “Two trials have evaluated ARBs in the context of STEMI as alternatives to ACE-inhibitors: the OPTIMAAL trial with losartan (50 mg) failed to show superiority or non-inferiority over captopril (50 mg three times daily).(220) Conversely, the VALIANT trial compared valsartan alone (160 mg twice daily),”
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017, neutral): “An ARB, preferably valsartan, is an alternative to ACE inhibitors in patients with heart failure and/or LV systolic dysfunction, particularly those who are intolerant of ACE inhibitors.(396,407) I B”
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, critical): “A similar trial with losartan (OPTIMAAL) did not demonstrate non-inferiority as compared with captopril.(115,116)”